Resources and Workforce Development for Research on NIH/NIAID High Priority Pathogens at the University of Missouri Regional Biocontainment Laboratory
Resources and Workforce Development for Research on NIH/NIAID High Priority Pathogens at the University of Missouri Regional Biocontainment Laboratory
批准号:
10793827
负责人:
Wendy L Picking
金额:
$259.55万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-08-18 至 2028-07-31
关键词:
2019-nCoVAccelerationAddressAdoptionAnimal HousingAnimal ModelAppointmentArbovirusesAreaAwardCOVID-19COVID-19 pandemicCommunicable DiseasesCommunitiesCore FacilityDecontaminationDedicationsDevelopmentDisease OutbreaksDisinfectantsEmerging Communicable DiseasesEquipmentEvaluationEventEvolutionFacultyFundingFutureGoalsGrantGrowthHumanHuman ResourcesImageImmunologyInfectionInfectious Diseases ResearchInfluenzaInfrastructureInstitutionInvestmentsKnowledgeLaboratoriesLeadershipMaintenanceMicrobiologyMidwestern United StatesMissionMissouriModernizationNamesNational Institute of Allergy and Infectious DiseaseNational SecurityOutputPhasePreparationPrevention approachProductivityPublic HealthRegulationResearchResearch PersonnelResearch SupportResource DevelopmentResourcesRoleSafetyScientistSecureSecuritySenior ScientistServicesSystemTechnologyTrainingUnited States National Institutes of HealthUniversitiesVirusWorkWorkforce Developmentanimal model developmentbiodefensecombatcoronavirus diseaseexperienceimprovedinstrumentationlaboratory experimentmedical countermeasuremembermicrobialnew outbreaknew technologynext generationnovelnovel strategiesoperationpandemic diseasepandemic potentialpandemic preparednesspathogenpreventpriority pathogenprogramspublic health relevancerecruitresearch and developmentresponsesynergismtransmission processvaccine platformvector-borne
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Overall Project Summary
Resources and Workforce Development for Research on NIH/NIAID High Priority Pathogens at the University
of Missouri Regional Biocontainment Laboratory
The University of Missouri Regional Biocontainment Laboratory (RBL) was commissioned in 2009 as an $18M,
12,377 NSF BSL-3/ABSL-3 facility. During its thirteen years of operation, the RBL, since named the MU
Laboratory for Infectious Disease Research (LIDR) has been a centerpiece of the broader infectious disease
research community at the University of Missouri, receiving strong institutional commitment in the recruitment
and sustainment of world-class faculty for management of the RBL/LIDR and for conducting research on high
priority pathogens. The LIDR operates shared research resources, including state-of-the-art equipment and
professional services in microbiology, aerobiology, immunology, and animal model core facilities that serve the
needs of researchers on campus and in the broader regional and national communities. The faculty and
professional staff of the LIDR are part of the NIH/NIAID RBL-NBL network, with collaborative interactions that
facilitate sharing of best practices and knowledge, providing synergy in achieving our collective biodefense and
emerging infectious disease research agenda. During the COVID pandemic, the MU LIDR, along with its RBL
and NBL partners, led the response to the pandemic and are committed to strengthening pandemic
preparedness of the nation, by providing BSL-3/ABSL-3 training, professional staff, and research services that
allow for rapid responses in all areas, including development of animal models and the evaluation of numerous
treatments, disinfectants, and vaccine platforms to combat the pandemic. The long-term goal of the present
application is to sustain a leading effort for development of novel medical countermeasures for combating the
ever present and changing threats of emerging and re-emerging infectious diseases, while training an
outstanding cadre of next generation scientists and professionals in biocontainment. The goals of the proposed
cores in Facility Management, Maintenance and Operations, BSL3 Practices, and Biocontainment Research
Support Services are to educate and train the next generation of scientists and biocontainment professionals in
biodefense and emerging infectious diseases, and to facilitate and enhance the development of novel
approaches for prevention and treatment of infections caused by high consequence pathogens whose natural
or deliberate transmission pose a threat to public health and national security. Towards these goals, the proposed
Cores will work within the broader infectious disease community at MU and the NIH/NIAID RBL-NBL network for
enhancement of research productivity and discovery, and continued sharing of information and best practices in
order to meet the changing priorities and needs of NIH/NIAID for biodefense and emerging infectious diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
An intranasal room stable vaccine formulation to prevent Pseudomonas aeruginosa (R21AI169691)
-
批准号:10741018
-
项目类别:
-
资助金额:$22.97万
-
财政年份:2023
-
负责人:Wendy L Picking
-
依托单位:
A prophylactic vaccine to prevent colonization by Pseudomonas aeruginosa
-
批准号:10582221
-
项目类别:
-
资助金额:$80.07万
-
财政年份:2022
-
负责人:Wendy L Picking
-
依托单位:
A vaccine specifically targeting T3SS-negative Pseudomonas aeruginosa
-
批准号:10636201
-
项目类别:
-
资助金额:$19.56万
-
财政年份:2021
-
负责人:Wendy L Picking
-
依托单位:
A vaccine specifically targeting T3SS-negative Pseudomonas aeruginosa
-
批准号:10313003
-
项目类别:
-
资助金额:$22.73万
-
财政年份:2021
-
负责人:Wendy L Picking
-
依托单位:
Vaccines to counter emerging antibiotic resistance
-
批准号:10155392
-
项目类别:
-
资助金额:$112.13万
-
财政年份:2018
-
负责人:Wendy L Picking
-
依托单位:
Vaccines to counter emerging antibiotic resistance (R01AI138970)
-
批准号:10738666
-
项目类别:
-
资助金额:$125.82万
-
财政年份:2018
-
负责人:Wendy L Picking
-
依托单位:
Vaccines to counter emerging antibiotic resistance
-
批准号:9918856
-
项目类别:
-
资助金额:$112.14万
-
财政年份:2018
-
负责人:Wendy L Picking
-
依托单位:
Development of a broadly protective subunit vaccine against Pseudomonas aeruginosa
-
批准号:9763456
-
项目类别:
-
资助金额:$23.79万
-
财政年份:2018
-
负责人:Wendy L Picking
-
依托单位:
Development of a next generation vaccine to prevent pertussis
-
批准号:9473234
-
项目类别:
-
资助金额:$22.73万
-
财政年份:2017
-
负责人:Wendy L Picking
-
依托单位:
Assessment of serotype-independent immunity elicited by Shigella T3SS proteins.
-
批准号:9107330
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2014
-
负责人:Wendy L Picking
-
依托单位:
Assessment of serotype-independent immunity elicited by Shigella T3SS proteins.
-
批准号:8766766
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2014
-
负责人:Wendy L Picking
-
依托单位:
Stable needleless vaccine against Shigella spp
-
批准号:8845510
-
项目类别:
-
资助金额:$18.7万
-
财政年份:2014
-
负责人:Wendy L Picking
-
依托单位:
Assessment of serotype-independent immunity elicited by Shigella T3SS proteins.
-
批准号:8900942
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2014
-
负责人:Wendy L Picking
-
依托单位:
Stable needleless vaccine against Shigella spp
-
批准号:8638140
-
项目类别:
-
资助金额:$23.59万
-
财政年份:2014
-
负责人:Wendy L Picking
-
依托单位:
Control of Type III secretion in Shigella by lpaD
-
批准号:7348356
-
项目类别:
-
资助金额:$34.81万
-
财政年份:2007
-
负责人:Wendy L Picking
-
依托单位:
IpaD triggers type III secretion in Shigella
-
批准号:7457910
-
项目类别:
-
资助金额:$7.06万
-
财政年份:2007
-
负责人:Wendy L Picking
-
依托单位:
Control of Type III secretion in Shigella by lpaD
-
批准号:7779872
-
项目类别:
-
资助金额:$36.87万
-
财政年份:2007
-
负责人:Wendy L Picking
-
依托单位:
Control of Type III secretion in Shigella by lpaD
-
批准号:7565918
-
项目类别:
-
资助金额:$7.45万
-
财政年份:2007
-
负责人:Wendy L Picking
-
依托单位:
Control of Type III secretion in Shigella by lpaD
-
批准号:7760585
-
项目类别:
-
资助金额:$35.61万
-
财政年份:2007
-
负责人:Wendy L Picking
-
依托单位:
Control of Type III secretion in Shigella by lpaD
-
批准号:7261606
-
项目类别:
-
资助金额:$35.5万
-
财政年份:2007
-
负责人:Wendy L Picking
-
依托单位:
海外基金